HOT NEWS
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon » Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trial...
Nycomed on track in 2009 with strong growth in Key Products » Nycomed was on track in 2009, with strong growth in Key Products and most emerging markets. Pantopra...
Bayer Successful in a Difficult Environment » 2009 was operationally one of the strongest years for the Bayer Group. "We were successful in a diff...
Phase III study of Avastin in advanced stomach cancer did not meet primary endpo... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the topline results from a global phase III trial inves...
Sanofi Pasteur's A(H1N1) Vaccine HUMENZA®* Recommended by European Medicines Ag... » Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announc...
FY2009: Merck KGaA Revenues Rise by 2.1% to € 7.7 Billion » Merck KGaA announced that Group total revenues rose 2.1% in 2009 - meeting the guidance given earlie...
GSK receives positive opinions in Europe for Tyverb® and Votrient™ » GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Product...
My child matters Supports Seven New Childhood Cancer Care Projects » On the International Childhood Cancer Day, the International Union Against Cancer (UICC) and sanofi-...
Abbott Completes Acquisition of Solvay Pharmaceuticals » Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisit...
Merck Receives European Approval for ELONVA® (corifollitropin alfa injection) » Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European C...
AstraZeneca
AstraZenecaAstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com.

AstraZeneca RSS Channel
Filter     Display # 
# Article Title Hits
1 AstraZeneca Fourth Quarter and Full Year Results 2009 439
2 AstraZeneca to Acquire Infection Research Company Novexel 492
3 AstraZeneca PLC Third Quarter & Nine Months Results 2009 353
4 AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) 474
5 AstraZeneca Submits Marketing Authorisation Application to European Union for VIMOVO™ 806
6 ONGLYZA (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabete 637
7 Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks 601
8 IRESSA (Gefitinib) Receives Marketing Authorisation in Europe 763
9 ONGLYZA (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes 960
10 AstraZeneca and Abbott Extend Relationship to Include Co-Promotion of Trilipix 618
11 AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration 646
12 AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA 672
13 IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe 661
14 AstraZeneca PLC Fourth Quarter and Full Year Results 2008 670
15 MedImmune's Application for Intranasal Vaccine to Prevent Seasonal Influenza 756
16 AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration 542
17 AstraZeneca to divest Nordic over-the-counter portfolio 473
18 AstraZeneca PLC Third Quarter and Nine Months Results 2008 239
19 AstraZeneca PLC Third Quarter and Nine Months Results 2008 368
 
Bookmark and Share

Banner